The 2014–2015 outbreak of Ebola virus disease is the largest epidemic to date in terms of
the number of cases, deaths, and affected areas. In October 2015, no antiviral agents had …

Plasma therapy consists in bringing to a patient in need–in general suffering a severe,
resistant to current therapy, and even lethal infection–plasma or specific, fractioned …

Background Available data on the characteristics of patients with Ebola virus disease (EVD)
and clinical management of EVD in settings outside West Africa, as well as the …

Background TKM-130803, a small interfering RNA lipid nanoparticle product, has been
developed for the treatment of Ebola virus disease (EVD), but its efficacy and safety in …

As of 20 May 2016 there have been 28,646 cases and 11,323 deaths resulting from the
West African Ebola virus disease (EVD) outbreak reported to the World Health Organization …

Small interfering RNA (siRNA) is a promising drug candidate, expected to have broad
therapeutic potentials toward various diseases including viral infections and cancer. With …

The clinical evaluation of convalescent plasma (CP) for the treatment of Ebola virus disease
(EVD) in the current outbreak, predominantly affecting Guinea, Sierra Leone, and Liberia …

Abstract Background The diagnosis of Ebola virus disease relies on the detection of viral
RNA in blood by real-time reverse-transcription PCR. While several of these assays were …

There are 4 families of viruses that cause viral hemorrhagic fever (VHF), including
Filoviridae. Ebola virus is one virus within the family Filoviridae and the cause of the current …

The recent Ebola virus (EBOV) outbreak in West Africa was the deadliest EBOV epidemic in
history, highlighting the need for a safe and efficacious treatment against EBOV disease …